Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Identification of an integrated SV40 T/t-antigen cancer signature in aggressive human breast, prostate, and lung carcinomas with poor prognosis.

Deeb KK, Michalowska AM, Yoon CY, Krummey SM, Hoenerhoff MJ, Kavanaugh C, Li MC, Demayo FJ, Linnoila I, Deng CX, Lee EY, Medina D, Shih JH, Green JE.

Cancer Res. 2007 Sep 1;67(17):8065-80. Erratum in: Cancer Res. 2007 Oct 15;67(20):10097.

2.

Molecular characterization of the Ggamma-globin-Tag transgenic mouse model of hormone refractory prostate cancer: comparison to human prostate cancer.

Calvo A, Perez-Stable C, Segura V, Catena R, Guruceaga E, Nguewa P, Blanco D, Parada L, Reiner T, Green JE.

Prostate. 2010 May 1;70(6):630-45. doi: 10.1002/pros.21097.

3.

Pathologic progression of mammary carcinomas in a C3(1)/SV40 T/t-antigen transgenic rat model of human triple-negative and Her2-positive breast cancer.

Hoenerhoff MJ, Shibata MA, Bode A, Green JE.

Transgenic Res. 2011 Apr;20(2):247-59. doi: 10.1007/s11248-010-9406-5. Epub 2010 Jun 12.

4.

Initiating oncogenic event determines gene-expression patterns of human breast cancer models.

Desai KV, Xiao N, Wang W, Gangi L, Greene J, Powell JI, Dickson R, Furth P, Hunter K, Kucherlapati R, Simon R, Liu ET, Green JE.

Proc Natl Acad Sci U S A. 2002 May 14;99(10):6967-72. Erratum in: Proc Natl Acad Sci U S A 2002 Jul 23;99(15):10227.

5.

Proteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with potential diagnostic and prognostic value in human breast cancer.

Warmoes M, Jaspers JE, Pham TV, Piersma SR, Oudgenoeg G, Massink MP, Waisfisz Q, Rottenberg S, Boven E, Jonkers J, Jimenez CR.

Mol Cell Proteomics. 2012 Jul;11(7):M111.013334. doi: 10.1074/mcp.M111.013334. Epub 2012 Feb 24.

6.

Global expression profiling identifies signatures of tumor virulence in MMTV-PyMT-transgenic mice: correlation to human disease.

Qiu TH, Chandramouli GV, Hunter KW, Alkharouf NW, Green JE, Liu ET.

Cancer Res. 2004 Sep 1;64(17):5973-81.

7.

Integrated miRNA and mRNA expression profiling of mouse mammary tumor models identifies miRNA signatures associated with mammary tumor lineage.

Zhu M, Yi M, Kim CH, Deng C, Li Y, Medina D, Stephens RM, Green JE.

Genome Biol. 2011 Aug 16;12(8):R77. doi: 10.1186/gb-2011-12-8-r77.

8.

The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma.

Green JE, Shibata MA, Yoshidome K, Liu ML, Jorcyk C, Anver MR, Wigginton J, Wiltrout R, Shibata E, Kaczmarczyk S, Wang W, Liu ZY, Calvo A, Couldrey C.

Oncogene. 2000 Feb 21;19(8):1020-7. Review.

9.
10.

Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer.

Arendt LM, Rugowski DE, Grafwallner-Huseth TA, Garcia-Barchino MJ, Rui H, Schuler LA.

Breast Cancer Res. 2011 Jan 28;13(1):R11. doi: 10.1186/bcr2819.

11.

A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies.

Shames DS, Girard L, Gao B, Sato M, Lewis CM, Shivapurkar N, Jiang A, Perou CM, Kim YH, Pollack JR, Fong KM, Lam CL, Wong M, Shyr Y, Nanda R, Olopade OI, Gerald W, Euhus DM, Shay JW, Gazdar AF, Minna JD.

PLoS Med. 2006 Dec;3(12):e486.

12.

Abrogation of junctional adhesion molecule-A expression induces cell apoptosis and reduces breast cancer progression.

Murakami M, Giampietro C, Giannotta M, Corada M, Torselli I, Orsenigo F, Cocito A, d'Ario G, Mazzarol G, Confalonieri S, Di Fiore PP, Dejana E.

PLoS One. 2011;6(6):e21242. doi: 10.1371/journal.pone.0021242. Epub 2011 Jun 17.

13.

Expression of a neuroendocrine gene signature in gastric tumor cells from CEA 424-SV40 large T antigen-transgenic mice depends on SV40 large T antigen.

Ihler F, Vetter EV, Pan J, Kammerer R, Debey-Pascher S, Schultze JL, Zimmermann W, Enders G.

PLoS One. 2012;7(1):e29846. doi: 10.1371/journal.pone.0029846. Epub 2012 Jan 13.

14.

Prostate cancer progression, metastasis, and gene expression in transgenic mice.

Perez-Stable C, Altman NH, Mehta PP, Deftos LJ, Roos BA.

Cancer Res. 1997 Mar 1;57(5):900-6.

15.

CREB targets define the gene expression signature of malignancies having reduced levels of the tumor suppressor tristetraprolin.

Fallahi M, Amelio AL, Cleveland JL, Rounbehler RJ.

PLoS One. 2014 Dec 26;9(12):e115517. doi: 10.1371/journal.pone.0115517. eCollection 2014.

16.

Transgenic expression of polyomavirus middle T antigen in the mouse prostate gives rise to carcinoma.

Lee SH, Jia S, Zhu Y, Utermark T, Signoretti S, Loda M, Schaffhausen B, Roberts TM.

J Virol. 2011 Jun;85(11):5581-92. doi: 10.1128/JVI.02609-10. Epub 2011 Mar 16.

17.

Stromal responses among common carcinomas correlated with clinicopathologic features.

Chen JL, Espinosa I, Lin AY, Liao OY, van de Rijn M, West RB.

Clin Cancer Res. 2013 Sep 15;19(18):5127-35. doi: 10.1158/1078-0432.CCR-12-3127. Epub 2013 Jun 26.

19.

Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene.

Maroulakou IG, Anver M, Garrett L, Green JE.

Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):11236-40.

20.

Mammary tumor formation and metastasis evoked by a HER2 splice variant.

Alajati A, Sausgruber N, Aceto N, Duss S, Sarret S, Voshol H, Bonenfant D, Bentires-Alj M.

Cancer Res. 2013 Sep 1;73(17):5320-7. doi: 10.1158/0008-5472.CAN-12-3186. Epub 2013 Jul 18.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk